Susana Araujo1, Sara Bañón1, Isabel Machuca1, Ana Moreno1, María J Pérez-Elías1, José L Casado2. 1. Department of Infectious DiseasesRamon y Cajal Hospital, Cra. Colmenar, Km 9.1, 28034 Madrid, Spain. 2. Department of Infectious DiseasesRamon y Cajal Hospital, Cra. Colmenar, Km 9.1, 28034 Madrid, Spain jose.casado@salud.madrid.org.
Abstract
OBJECTIVE: HIV-infected patients had a higher prevalence of insulin resistance (IR) and risk of diabetes mellitus (DM) than that observed in healthy controls, but there are no data about the current prevalence considering the changes in HIV presentation and the use of newer antiretroviral drugs. DESIGN: Longitudinal study which involved 265 HIV patients without DM, receiving first (n=71) and advanced lines of antiretroviral therapy (n=194). METHODS: Prevalence of IR according to clinical and anthropometric variables, including dual X-ray absorptiometry (DXA) scan evaluation. IR was defined as homeostasis model assessment of IR≥3.8. Incident DM was assessed during the follow-up. RESULTS: First-line patients had a short time of HIV infection, less hepatitis C virus coinfection, and received mainly an efavirenz-based regimen. Overall, the prevalence of IR was 21% (55 patients, 6% in first-line, 27% in pretreated). In a logistic regression analysis, significant associations were found between the waist/hip circumference ratio (RR 10; 95% CI 1.66-16; P<0.01, per unit), and central fat in percentage (RR 1.08; 95% CI 1.01-1.17; P=0.04, per unit) as evaluated by DXA, and IR. During 770.8 patient-years, DM was diagnosed in 8% (22 patients), mostly in pretreated patients (10 vs 4%; P=0.1). Thus, the overall rate of incident DM was 2.85 per 100 person-years, mostly in previous IR (10.39 vs 0.82/100 person-years; P=0.01). CONCLUSIONS: A lower prevalence of IR is observed in the current HIV-infected patients with fewer risk factors and receiving newer antiretroviral drugs. IR continues to identify patients at high risk for developing DM in the short term.
OBJECTIVE:HIV-infectedpatients had a higher prevalence of insulin resistance (IR) and risk of diabetes mellitus (DM) than that observed in healthy controls, but there are no data about the current prevalence considering the changes in HIV presentation and the use of newer antiretroviral drugs. DESIGN: Longitudinal study which involved 265 HIVpatients without DM, receiving first (n=71) and advanced lines of antiretroviral therapy (n=194). METHODS: Prevalence of IR according to clinical and anthropometric variables, including dual X-ray absorptiometry (DXA) scan evaluation. IR was defined as homeostasis model assessment of IR≥3.8. Incident DM was assessed during the follow-up. RESULTS: First-line patients had a short time of HIV infection, less hepatitis C virus coinfection, and received mainly an efavirenz-based regimen. Overall, the prevalence of IR was 21% (55 patients, 6% in first-line, 27% in pretreated). In a logistic regression analysis, significant associations were found between the waist/hip circumference ratio (RR 10; 95% CI 1.66-16; P<0.01, per unit), and central fat in percentage (RR 1.08; 95% CI 1.01-1.17; P=0.04, per unit) as evaluated by DXA, and IR. During 770.8 patient-years, DM was diagnosed in 8% (22 patients), mostly in pretreated patients (10 vs 4%; P=0.1). Thus, the overall rate of incident DM was 2.85 per 100 person-years, mostly in previous IR (10.39 vs 0.82/100 person-years; P=0.01). CONCLUSIONS: A lower prevalence of IR is observed in the current HIV-infectedpatients with fewer risk factors and receiving newer antiretroviral drugs. IR continues to identify patients at high risk for developing DM in the short term.
Authors: Melissa Herrin; Janet P Tate; Kathleen M Akgün; Adeel A Butt; Kristina Crothers; Matthew S Freiberg; Cynthia L Gibert; David A Leaf; David Rimland; Maria C Rodriguez-Barradas; Chris B Ruser; Kevan C Herold; Amy C Justice Journal: J Acquir Immune Defic Syndr Date: 2016-10-01 Impact factor: 3.731
Authors: Yisel M Cantres-Rosario; Valerie Wojna; Rafael Ruiz; Bexaida Diaz; Miriam Matos; Rosa J Rodriguez-Benitez; Elaine Rodriguez; Richard L Skolasky; Yamil Gerena Journal: Front Neurol Date: 2022-06-02 Impact factor: 4.086
Authors: Eduard Tiozzo; Allan Rodriguez; Janet Konefal; Gary J Farkas; Jennifer L Maher; John E Lewis Journal: Int J Environ Res Public Health Date: 2021-04-08 Impact factor: 3.390
Authors: Jordan E Lake; Xiuhong Li; Frank J Palella; Kristine M Erlandson; Dorothy Wiley; Lawrence Kingsley; Lisa P Jacobson; Todd T Brown Journal: AIDS Date: 2018-01-02 Impact factor: 4.632
Authors: Marshall J Glesby; David B Hanna; Donald R Hoover; Qiuhu Shi; Michael T Yin; Phyllis C Tien; Mardge Cohen; Kathryn Anastos; Anjali Sharma Journal: AIDS Date: 2018-07-31 Impact factor: 4.632
Authors: Stefany D Primeaux; Liz Simon; Tekeda F Ferguson; Danielle E Levitt; Meghan M Brashear; Alice Yeh; Patricia E Molina Journal: Alcohol Clin Exp Res Date: 2021-08-02 Impact factor: 3.928